Checkpoint inhibitor induced colitis

Last updated
Checkpoint inhibitor induced colitis
Specialty Gastroenterology
Symptoms Diarrhea, abdominal pain, rectal bleeding
Complications Perforation, toxic megacolon
Usual onset~6-7 weeks after starting checkpoint inhibitor [1]
CausesCancer immunotherapy treatment
Risk factors Caucasian, NSAID use, anti-CTLA4 treatment, melanoma, history of prior checkpoint inhibitor induced colitis, Faecalibacterium in fecal microbiota
Diagnostic method Colonoscopy, stool tests for infection
Differential diagnosis Infectious colitis, gastrointestinal metastases (rare)
PreventionNone
Treatment Corticosteroids, infliximab, vedolizumab
Prognosis Associated with improved overall survival
Frequency0.7 – 1.6% (anti-PD1)
5.7 – 9.1% (anti-CTLA-4)
13.6% (combination therapy)

Checkpoint inhibitor induced colitis is an inflammatory condition affecting the colon (colitis), which is caused by cancer immunotherapy (checkpoint inhibitor therapy). Symptoms typically consist of diarrhea, abdominal pain and rectal bleeding. Less commonly, nausea and vomiting may occur, which may suggest the present of gastroenteritis. The severity of diarrhea and colitis are graded based on the frequency of bowel movements and symptoms of colitis, respectively.

Contents

The gold standard for the diagnosis of checkpoint inhibitor induced colitis is colonoscopy with evaluation of the terminal ileum. However, in most cases, a flexible sigmoidoscopy is sufficient. Infection should be ruled out with stool studies, including Clostridioides difficile, bacterial culture, ova and parasites. Symptoms of upper abdominal pain, nausea or vomiting warrant evaluation with upper endoscopy.

Treatment of immune checkpoint inhibitor colitis is based on severity, as defined by the grade of diarrhea and colitis. Mild cases by managed with temporary interruption of immune checkpoint inhibitor therapy, dietary modification (low residue), and/or loperamide. More severe cases require immune suppression with corticosteroid therapy. If steroids are ineffective, infliximab may be considered. If colitis fails to improve with infliximab, then vedolizumab may be effective.

Signs and symptoms

The most common symptom is diarrhea, which occurs in 92 percent of cases, followed by abdominal pain (82%) and rectal bleeding (64%). [2] About 46% of cases include fever and 36% involve nausea and vomiting. [2] Less often, nausea and vomiting may be present. Weight loss has been reported. [1] Onset of diarrhea generally occurs about 6–7 weeks after starting immune checkpoint inhibitor therapy. [1]

Grading colitis and diarrhea

The extent of diarrhea is graded based on severity, from 1 to 5. Grade 1 diarrhea is defined by an increase in the number of stools below four per day (compared with baseline). Grade 2 diarrhea is defined by an increase of 4–6 bowel movements per day. Grade 3 diarrhea is defined by an increase by 7 or more bowel movements per day. Grade 4 diarrhea involves life-threatening consequences, such as shock, whereas grade 5 results in death.

The extent of colitis is also graded based on severity, from 1 to 5. Grade 1 colitis does not result in any symptoms, while grade 2 colitis leads to abdominal pain, mucous and blood in the stools. Grade 3 colitis is defined by severe pain, peritoneal signs and ileus. Grade 4 colitis is defined by life-threatening consequences, including perforation, ischemia, necrosis, bleeding, or toxic megacolon. Grade 5 colitis results in death.

Complications

High grade colitis may lead to severe complications, including perforation, toxic megacolon and death. Bleeding may occur due to colitis. Treatment with corticosteroids may lead to infectious complications, including: urinary tract infections, C. difficile infection, and pneumonia. [3]

Pathophysiology

Immune checkpoints are important for the normal development of T regulatory cells (Tregs) in the intestine. Mice with the CTLA-4 gene removed (eg CTLA-4 knockout) develop severe autoimmune disease, with diffuse infiltration of T cells in multiple organs and fatal enterocolitis. [2]

Immune checkpoint inhibitor colitis is typically characterized by either diffuse mucosal inflammation or focal active colitis with patchy crypt abscesses. [4] Common findings of acute colitis include: intraepithelial neutrophilic infiltrates, crypt abscesses, and increased apoptotic cells within crypts. However, the histologic appearance varies, and evidence of chronic inflammation is seen in some cases, including intraepithelial lymphocytes or basal lymphocytes and crypt architecture distortion. [4] Histologic inflammation may occur as early as 1–2 weeks after immune checkpoint inhibitor therapy, well before the onset of symptoms. [4]

Anti-PD-1 induced colitis may lead to more CD8+ T cell inflammation, whereas Anti-CTLA4 induced colitis may involve more CD4+ T cell infiltration and higher mucosal levels of the inflammatory molecule TNF alpha.

Amongst people treated with immune checkpoint inhibitors, those with Faecalibacterium genus and other Bacillota present in the colonic flora have longer progression-free survival and overall survival. In addition, a higher rate of checkpoint inhibitor induced colitis is associated with the presence of Faecalibacterium in the fecal microbiota. [5]

Diagnosis

Colonoscopy with evaluation of the terminal ileum is the gold standard in the diagnosis of checkpoint inhibitor induced colitis. [4] [2] However, in most cases, a limited evaluation of the distal colon with flexible sigmoidoscopy is sufficient. [4] [2] [6] Endoscopic findings may include loss of vascular pattern, erythema, edema, erosions, ulcers, exudates, granularity, and bleeding. [1] [7] Biopsies should be taken even in endoscopic findings are normal, as inflammation may not be immediately apparent and may only be seen on histology (microscopic colitis). [4]

Symptoms of nausea, vomiting and epigastric pain may suggest involvement of the upper gastrointestinal tract. If present, evaluation with upper endoscopy is warranted. [4]

There are no stool tests or blood tests specific for checkpoint inhibitor induced colitis. [1] However, diagnostic evaluation should include ruling out infectious causes for diarrhea and colitis. [4] Stool studies should include: Clostridioides difficile toxin, bacterial culture, ova and parasites. Testing for CMV infection should be considered. [4] Fecal calprotectin may be helpful, and is very sensitive and specific for inflammation in the intestines. [4] Elevations in fecal calprotectin correlate with the extent of intestinal inflammation. [2]

Computed tomography (CT) imaging may show evidence of colitis, though the sensitivity is relatively low (50%). [1] Free air in the peritoneum indicates bowel perforation. [1] Abdominal imaging may be necessary to rule out toxic megacolon or perforation. [1]

Though rare, gastrointestinal metastases (rare) should be considered as a cause of symptoms. [4]

Treatment

Treatment varies depending on the severity of disease. For mild disease, supportive care may be sufficient, including loperamide and a low residue or bland diet. For more severe disease, the immune checkpoint inhibitor should be discontinued. Corticosteroid therapy is used to decrease inflammation, at a dose of roughly prednisone 1–2 mg per kg of body weight per day. In cases that do not respond to corticosteroid therapy, infliximab may be used. For cases that fail to respond to infliximab, or where infliximab is contraindicated, vedolizumab may be used. [8] Overall, response rates from treatment are 59% for corticosteroids, 81% for infliximab, and 85% for vedolizumab. [9]

Surgery with resection of the colon (colectomy) is necessary in some instances, [10] particularly if severe complications occur, such as perforation [1] or toxic megacolon.

Fecal calprotectin, a stool test and marker of inflammation, may be used to follow improvement in colitis. [8]

Epidemiology

The prevalence of checkpoint inhibitor induced colitis varies depending on the regimen of immunotherapy. The incidence is 0.7 – 1.6% for anti-programmed cell death protein 1 (PD1) agents, 5.7 – 9.1% for anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and about 13.6% for combination therapy. [2] The risk associated with ipilimumab is dose dependent, such that higher doses are associated with higher rates of colitis. [11] However, other agents (nivolumab and pembrolizumab) are not associated with a dose dependent effect on the risk of immune mediated colitis. [11]

Risk factors for immune mediated colitis include Caucasian race, treatment with an anti-CTLA4 based regimen, melanoma as cancer type, [3] nonsteroidal anti-inflammatory drug (NSAID) use, [8] and a prior history of checkpoint inhibitor induced colitis.

See also

Related Research Articles

<span class="mw-page-title-main">Ulcerative colitis</span> Inflammatory bowel disease that causes ulcers in the colon

Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood (hematochezia). Weight loss, fever, and anemia may also occur. Often, symptoms come on slowly and can range from mild to severe. Symptoms typically occur intermittently with periods of no symptoms between flares. Complications may include abnormal dilation of the colon (megacolon), inflammation of the eye, joints, or liver, and colon cancer.

<span class="mw-page-title-main">Infliximab</span> Pharmaceutical drug

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Enteritis is inflammation of the small intestine. It is most commonly caused by food or drink contaminated with pathogenic microbes, such as Serratia, but may have other causes such as NSAIDs, radiation therapy as well as autoimmune conditions like Crohn's disease and celiac disease. Symptoms include abdominal pain, cramping, diarrhea, dehydration, and fever. Related diseases of the gastrointestinal system include inflammation of the stomach and large intestine.

<span class="mw-page-title-main">Abdominal pain</span> Stomach aches

Abdominal pain, also known as a stomach ache, is a symptom associated with both non-serious and serious medical issues.

<span class="mw-page-title-main">Gastrointestinal disease</span> Medical condition

Gastrointestinal diseases refer to diseases involving the gastrointestinal tract, namely the esophagus, stomach, small intestine, large intestine and rectum, and the accessory organs of digestion, the liver, gallbladder, and pancreas.

<span class="mw-page-title-main">Colitis</span> Inflammation of the colon (large intestine)

Colitis is swelling or inflammation of the large intestine (colon). Colitis may be acute and self-limited or long-term. It broadly fits into the category of digestive diseases.

<span class="mw-page-title-main">Alosetron</span> Medication

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

<span class="mw-page-title-main">Toxic megacolon</span> Medical condition

Toxic megacolon is an acute form of colonic distension. It is characterized by a very dilated colon (megacolon), accompanied by abdominal distension (bloating), and sometimes fever, abdominal pain, or shock.

<span class="mw-page-title-main">Megacolon</span> Medical condition

Megacolon is an abnormal dilation of the colon. This leads to hypertrophy of the colon. The dilation is often accompanied by a paralysis of the peristaltic movements of the bowel. In more extreme cases, the feces consolidate into hard masses inside the colon, called fecalomas, which can require surgery to be removed.

<span class="mw-page-title-main">Radiation proctitis</span> Medical condition

Radiation proctitis or radiation proctopathy is a condition characterized by damage to the rectum after exposure to x-rays or other ionizing radiation as a part of radiation therapy. Radiation proctopathy may occur as acute inflammation called "acute radiation proctitis" or with chronic changes characterized by radiation associated vascular ectasiae (RAVE) and chronic radiation proctopathy. Radiation proctitis most commonly occurs after pelvic radiation treatment for cancers such as cervical cancer, prostate cancer, bladder cancer, and rectal cancer. RAVE and chronic radiation proctopathy involves the lower intestine, primarily the sigmoid colon and the rectum, and was previously called chronic radiation proctitis, pelvic radiation disease and radiation enteropathy.

<span class="mw-page-title-main">Neutropenic enterocolitis</span> Medical condition

Neutropenic enterocolitis, also known as typhlitis, is an inflammation of the cecum that may be associated with infection. It is particularly associated with neutropenia, a low level of neutrophil granulocytes in the blood.

<span class="mw-page-title-main">Descending colon</span>

In the anatomy of humans and homologous primates, the descending colon is the part of the colon extending from the left colic flexure to the level of the iliac crest. The function of the descending colon in the digestive system is to store the remains of digested food that will be emptied into the rectum.

Management of ulcerative colitis involves first treating the acute symptoms of the disease, then maintaining remission. Ulcerative colitis is a form of colitis, a disease of the intestine, specifically the large intestine or colon, that includes characteristic ulcers, or open sores, in the colon. The main symptom of active disease is usually diarrhea mixed with blood, of gradual onset which often leads to anaemia. Ulcerative colitis is, however, a systemic disease that affects many parts of the body outside the intestine.

<span class="mw-page-title-main">Biological therapy for inflammatory bowel disease</span>

Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. Even for diseases of unknown cause, molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. Many of these molecules, which are mainly cytokines, are directly involved in the immune system. Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

<span class="mw-page-title-main">Lubiprostone</span> Medication used for constipation

Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

Radiation enteropathy is a syndrome that may develop following abdominal or pelvic radiation therapy for cancer. Many affected people are cancer survivors who had treatment for cervical cancer or prostate cancer; it has also been termed pelvic radiation disease with radiation proctitis being one of the principal features.

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7, blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.

<span class="mw-page-title-main">Amoebiasis</span> Human disease caused by amoeba protists

Amoebiasis, or amoebic dysentery, is an infection of the intestines caused by a parasitic amoeba Entamoeba histolytica. Amoebiasis can be present with no, mild, or severe symptoms. Symptoms may include lethargy, loss of weight, colonic ulcerations, abdominal pain, diarrhea, or bloody diarrhea. Complications can include inflammation and ulceration of the colon with tissue death or perforation, which may result in peritonitis. Anemia may develop due to prolonged gastric bleeding.

<span class="mw-page-title-main">Segmental colitis associated with diverticulosis</span> Medical condition

Segmental colitis associated with diverticulosis (SCAD) is a condition characterized by localized inflammation in the colon, which spares the rectum and is associated with multiple sac-like protrusions or pouches in the wall of the colon (diverticulosis). Unlike diverticulitis, SCAD involves inflammation of the colon between diverticula, while sparing the diverticular orifices. SCAD may lead to abdominal pain, especially in the left lower quadrant, intermittent rectal bleeding and chronic diarrhea.

<span class="mw-page-title-main">Antiarthritics</span> Drug class

An antiarthritic is any member of the group of drugs used to relieve or prevent arthritic symptoms, such as joint pain and joint stiffness. Depending on the antiarthritic drug class, it can be responsible for managing pain, reducing inflammation and/or acting as an immunosuppressant. These drugs are typically given orally, topically or through administration by injection. The choice of antiarthritic medication is often determined by the type/nature of arthritis, the severity of symptoms as well as other factors, such as the tolerability of side effects.

References

  1. 1 2 3 4 5 6 7 8 9 Tian, Y; Abu-Sbeih, H; Wang, Y (2018). "Immune Checkpoint Inhibitors-Induced Colitis". Immunotherapy. Advances in Experimental Medicine and Biology. Vol. 995. pp. 151–157. doi:10.1007/978-3-030-02505-2_7. ISBN   978-3-030-02504-5. PMID   30539510.
  2. 1 2 3 4 5 6 7 Bellaguarda, Emanuelle; Hanauer, Stephen (February 2020). "Checkpoint Inhibitor–Induced Colitis". The American Journal of Gastroenterology. 115 (2): 202–210. doi: 10.14309/ajg.0000000000000497 . PMID   31922959.
  3. 1 2 Wang, Yinghong; Abu-Sbeih, Hamzah; Mao, Emily; Ali, Noman; Ali, Faisal Shaukat; Qiao, Wei; Lum, Phillip; Raju, Gottumukkala; Shuttlesworth, Gladis; Stroehlein, John; Diab, Adi (11 May 2018). "Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson". Journal for Immunotherapy of Cancer. 6 (1): 37. doi: 10.1186/s40425-018-0346-6 . PMC   5946546 . PMID   29747688.
  4. 1 2 3 4 5 6 7 8 9 10 11 Som, Aniruddh; Mandaliya, Rohan; Alsaadi, Dana; Farshidpour, Maham; Charabaty, Aline; Malhotra, Nidhi; Mattar, Mark C (26 February 2019). "Immune checkpoint inhibitor-induced colitis: A comprehensive review". World Journal of Clinical Cases. 7 (4): 405–418. doi: 10.12998/wjcc.v7.i4.405 . PMC   6397821 . PMID   30842952.
  5. ↑ Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F. (June 2017). "Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab". Annals of Oncology. 28 (6): 1368–1379. doi: 10.1093/annonc/mdx108 . PMID   28368458.
  6. ↑ Wright, AP; Piper, MS; Bishu, S; Stidham, RW (June 2019). "Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis". Alimentary Pharmacology & Therapeutics. 49 (12): 1474–1483. doi:10.1111/apt.15263. PMC   6637018 . PMID   31035308.
  7. ↑ Nishida, T; Iijima, H; Adachi, S (10 September 2019). "Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings". World Journal of Gastrointestinal Pathophysiology. 10 (2): 17–28. doi: 10.4291/wjgp.v10.i2.17 . PMC   6751508 . PMID   31559106.
  8. 1 2 3 Brahmer, Julie R.; Lacchetti, Christina; Schneider, Bryan J.; Atkins, Michael B.; Brassil, Kelly J.; Caterino, Jeffrey M.; Chau, Ian; Ernstoff, Marc S.; Gardner, Jennifer M.; Ginex, Pamela; Hallmeyer, Sigrun; Holter Chakrabarty, Jennifer; Leighl, Natasha B.; Mammen, Jennifer S.; McDermott, David F.; Naing, Aung; Nastoupil, Loretta J.; Phillips, Tanyanika; Porter, Laura D.; Puzanov, Igor; Reichner, Cristina A.; Santomasso, Bianca D.; Seigel, Carole; Spira, Alexander; Suarez-Almazor, Maria E.; Wang, Yinghong; Weber, Jeffrey S.; Wolchok, Jedd D.; Thompson, John A. (10 June 2018). "Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline". Journal of Clinical Oncology. 36 (17): 1714–1768. doi:10.1200/JCO.2017.77.6385. PMC   6481621 . PMID   29442540.
  9. ↑ Ibraheim, Hajir (2020). "Systematic review with meta‐analysis: effectiveness of anti‐inflammatory therapy in immune checkpoint inhibitor‐induced enterocolitis". Alimentary Pharmacology & Therapeutics. 52 (9): 1432–1452. doi: 10.1111/apt.15998 . PMID   32920854. S2CID   221672875.
  10. ↑ Spain, L; Diem, S; Larkin, J (March 2016). "Management of toxicities of immune checkpoint inhibitors". Cancer Treatment Reviews. 44: 51–60. doi:10.1016/j.ctrv.2016.02.001. PMID   26874776.
  11. 1 2 Kumar, V; Chaudhary, N; Garg, M; Floudas, CS; Soni, P; Chandra, AB (2017). "Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy". Frontiers in Pharmacology. 8: 49. doi: 10.3389/fphar.2017.00049 . PMC   5296331 . PMID   28228726.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.